MIRA's Ketamir-2 shows promise in treating diabetic neuropathy, with a Phase 2a trial expected by late 2025 and human data in ...

MIRA) on Wednesday released data demonstrating the efficacy of the oral ketamine analog, Ketamir-2, in a validated animal model of diabetic neuropathy, a type of nerve damage that can occur in ...

MIAMI, FLORIDA / ACCESS Newswire / April 16, 2025 / MIRA Pharmaceuticals ... Ketamir-2, in a validated animal model of diabetic neuropathy. In the study, Type 2 diabetes was induced in rats ...

MIAMI, FLORIDA / ACCESS Newswire / April 16, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ ... Ketamir-2, in a validated animal model of diabetic neuropathy. In the study, Type 2 diabetes was induced in ...

Ketamir-2 Demonstrates Strong Efficacy in Diabetic Neuropathy Model, with Some Subjects Achieving Complete Symptom Reversal ...